Table 1

Analysis of the patients with stage I NSCLC according to the methylation status of IGFBP-3 promoter

Methylated group (51/83)Unmethylated group (32/83)P
Age, yr, mean± SD64.7± 8.8366.2± 8.920.461
Gender, n (%)
Male33 (39.8)22 (26.5)
Female18 (21.7)10 (12.0)0.704
Pathology, n (%)
Adenocarcinoma28 (33.7)12 (14.5)
Squamous carcinoma21 (25.3)15 (18.1)
Others2 (2.4)5 (6.0)0.101
Histologic grade, n (%)
Well-differentiated3 (3.6)1 (1.2)
Moderately differentiated20 (24.1)11 (13.3)
Poorly differentiated20 (24.1)16 (19.3)
Undifferentiated/Anaplastic2 (2.4)1 (1.2)
Unclassified6 (7.2)3 (3.6)0.913
Smoking status, n (%)
Current, pack-year43 (51.8); 67.6± 40.8927 (32.5); 63.2± 34.190.643
Ex-smoker2 (2.4)0 (0.0)
Nonsmoker2 (2.4)1 (1.2)
Unknown4 (4.8)4 (4.8)
5-yr survival P (%) (95% CI)
Overall38.9 (27.3–55.4)64.0 (48.9–83.7)0.022
Disease specific53.1 (40.0–70.6)86.1 (74.3–99.8)0.006
Disease free36.5 (24.3–55.0)76.2 (62.3–93.3)0.007